New treatment for aggressive brain tumors using Zika virus
Validation of a novel treatment for glioblastoma using oncolytic Zika virus
This study is testing a new treatment using a special virus that targets and kills glioblastoma brain tumor cells while leaving healthy cells alone, and it's for patients looking for new options to fight this tough cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Up Oncolytics, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-10920797 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for glioblastoma multiforme (GBM), a highly aggressive brain tumor with a poor prognosis. The approach utilizes oncolytic Zika virus, which is designed to selectively target and destroy GBM cells while sparing healthy cells. The study aims to overcome significant treatment challenges, such as crossing the blood-brain barrier and addressing the tumor's immunoinhibitory environment. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma multiforme who have limited treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with glioblastoma, potentially improving survival rates.
How similar studies have performed: While the use of oncolytic viruses in cancer treatment is a growing field, this specific approach using Zika virus for glioblastoma is novel and has not been extensively tested in clinical settings.
Where this research is happening
Milwaukee, United States
- Up Oncolytics, INC. — Milwaukee, United States (Active)
Researchers
- Principal investigator: Akhtar, Parvez — Up Oncolytics, INC.
- Study coordinator: Akhtar, Parvez
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.